International Application No. PCT/EP2003/014538 : International Filing Date December 18, 2003 Priority Date(s) Claimed January 7, 2003 : Valerie AUTIER et al. Applicant(s) (DO/EO/US) Title: KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETES OF LANGERHANS CELLS INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Sir: This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: Timing and Fees Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information M disclosure statement is filed: within three months of the filing date of a national application other than a CPA under § 1.53(d); within three months of the actual filing date of the national phase of a PCT application; OR before the mailing of a first substantive office action (including after filing of an \boxtimes RCE). Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR

a final rejection under 37 C.F.R. 1.113;

a notice of allowance under 37 C.F.R. § 1.311; and

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).
Staten	nents Ui	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	<u>Materia</u>	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	\boxtimes	-	s of materials listed but not attached were cited in an international search dated <u>July 5, 2004</u> .
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

Non-E	English l	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	\boxtimes	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
		A = document defining the general state of the art O = non-written disclosure
		P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
		Translation of other relevant information on foreign search report
		[insert necessary translation here]
Other	Informa	ntion .
Payme	ent of F	ees Due (If Any):
		ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

10/541493

JC20 Rec'd PCT 0 7 JUL 2005

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3029

Date: July 7, 2005

AJZ:aap

K:\Merck\Merck 3000 - 3999\3029\Information Disclosure Statement.doc



JC20 Rec'd PCT/2005

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of 2

	Complete if Known
Application Number	100 sig 204 1 4 9 2
Filing Date	July 7,2005
First Named Inventor	Valerie AUTIER et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	MERCK-3029

	U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	1	5877193		Cesura Andrea et al.	March 2, 1999			
	2	6143787		Kergoat Micheline et al.	November 7, 2000			
	3_	2003166689			September 4, 2003			
	_ i							
			_					

		Foreign Patent Document		ment			Pages, Columns, Lines, Where	
Examiner Initials*	Cite No. ¹	Office ³	Number⁴	Kind Code⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		Т*
	4	EP	0885869		Japan Tobacco Inc	December 23, 1998		
	5	wo	0190092		Biovitrum AB	November 29, 2001		Equv to cite 3
				1				
				 				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



JC20 Rec'd PCT/F 0 7 JUL 2005

Please type a plus sign (+) inside this box	+
---	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute fo	or form 1449A/PT0)		Complete if Kaoyn I. O Z			
		-	01.001155	Application Number	Library Grant 14 9 3		
			CLOSURE	Filing Date	July 7, 2005		
STATEMENT BY APPLICANT		First Named Inventor	Valerie AUTIER et al.				
				Group Art Unit	Unassigned		
(6	use as many she	eets as	necessary)	Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	MERCK-3029	J	

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		NAOKI ET AL.: "A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta cells via a new cellular mechanism" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 297, no. 3, 2001, pages 953-960 XP002263095.	
	7	OHTA et al.: "JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats" EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 367, 1999, pages 91-99, XP002263096.	
	8	ESTOPINAN GARCIA V et al: "Perspectives of the immunosuppressive treatment for the prevention of diabetes mellitus type I" ANALES DE MEDICINA INTERNA 1992 SPAIN, vol. 9, no. 10, 1992, pages 471-472, XP009031857	
	9	MANDRUP-POULSEN T R ET AL: Cyclosporin immunosuppression induces clinical remission and improved 'beta!-cell function in newly diagnosed insulin-dependent diabetecs: A national and international multicentre study" UGESKRIFT FOR LAEGER 1990 DENMARK, vol.152, no. 27, 1990, pages 1963-1969, XP009031858	
	10	CONNICK ET AL.: "The role of kynurenines in diabetes mellitus" MEDICAL HYPOTHESES, vol.; 18, no, 4, 1985, pages 371-376, XP009021813	
			-

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.